trending Market Intelligence /marketintelligence/en/news-insights/trending/Ld7p4PzgHJyTh2FOAQvIyA2 content esgSubNav
In This List

Onxeo to record €38M impairment charge for 2017

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Onxeo to record €38M impairment charge for 2017

Onxeo SA said it will record an impairment charge of about €38 million to its 2017 financial statements in accordance with IFRS accounting standards.

The Paris-based biotechnology company said the charge notably stems from its research and development assets related to Beleodaq, its lymphoma drug. The company acquired the drug, valued at €63 million, in 2014 through its merger with Topotarget A/S.

The impairment charge is related to an increasingly competitive environment for Beleodaq in treating peripheral T-cell lymphoma, the company said.

The charge will not affect the company's current or future cash balance or its ability to advance its value creation strategy, Onxeo added.

"[T]he primary value driver for Onxeo for the foreseeable future is the continued development of AsiDNA, a first-in-class DNA damage response inhibitor with blockbuster potential and our lead product candidate. We expect to initiate a phase I study of AsiDNA as an anti-cancer monotherapy in the coming weeks, with results anticipated to be available by year-end," Onxeo CFO Nicolas Fellmann said in a statement.